Amgen Sees Unusually High Options Volume (AMGN)
Amgen (NASDAQ:AMGN) saw unusually large options trading on Monday. Stock traders acquired 23,340 call options on the company, AnalystRatings.Net reports. This is an increase of 292% compared to the average daily volume of 5,961 call options.
In other Amgen news, EVP Sean E. Harper sold 14,000 shares of Amgen stock on the open market in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $127.29, for a total value of $1,782,060.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on AMGN. Analysts at Argus reiterated a “buy” rating on shares of Amgen in a research note on Monday, August 4th. They now have a $140.00 price target on the stock, up previously from $135.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Amgen in a research note on Thursday, July 31st. They now have a $137.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Amgen from $135.00 to $140.00 in a research note on Thursday, July 31st. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $139.44.
Shares of Amgen (NASDAQ:AMGN) traded up 0.29% during mid-day trading on Monday, hitting $127.32. 2,529,181 shares of the company’s stock traded hands. Amgen has a 52 week low of $103.88 and a 52 week high of $131.24. The stock has a 50-day moving average of $121.5 and a 200-day moving average of $119.3. The company has a market cap of $96.713 billion and a price-to-earnings ratio of 19.44.
Amgen (NASDAQ:AMGN) last released its earnings data on Tuesday, July 29th. The company reported $2.37 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.07 by $0.30. The company had revenue of $5.18 billion for the quarter, compared to the consensus estimate of $4.90 billion. During the same quarter in the prior year, the company posted $1.89 earnings per share. The company’s quarterly revenue was up 10.7% on a year-over-year basis. On average, analysts predict that Amgen will post $8.37 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Friday, September 5th. Investors of record on Thursday, August 14th will be paid a dividend of $0.61 per share. This represents a $2.44 annualized dividend and a dividend yield of 1.92%. The ex-dividend date is Tuesday, August 12th.
Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.
Receive News & Ratings for Amgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.